ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors
01 July 2022 - 9:15PM
Business Wire
Ameet Mallik, Chief Executive Officer of ADC
Therapeutics, also joins the Board
ADC Therapeutics SA (NYSE: ADCT) today announced the appointment
of veteran oncology drug developer Jean-Pierre Bizzari, MD, to its
Board of Directors. Additionally, Ameet Mallik, who was appointed
as the Company’s Chief Executive Officer in May 2022, will join the
Board.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220701005047/en/
Jean-Pierre Bizzari, MD (Photo: Business
Wire)
“Jean-Pierre is an exceptional addition to our Board,” said Ron
Squarer, Chairman of ADC Therapeutics’ Board of Directors. “His
integral role in the development and approval of leading cancer
treatments across global markets will bring valuable perspective to
ADC Therapeutics as we advance a robust pipeline of ADCs for the
treatment of hematological cancers and solid tumors.”
Dr. Jean-Pierre Bizzari is an internationally renowned
oncologist with over 35 years of experience in oncology drug
development. He was Executive Vice President and Group Head of
Clinical Oncology Development at Celgene Corporation where he was
responsible for clinical development and operations across the
United States, Europe and Asia/Japan. During his tenure at Celgene,
he oversaw the development and approval of leading oncology
products including REVLIMID® (lenalidomide), VIDAZA® (azacytidine),
and ABRAXANE® (nab-paclitaxel). Dr. Bizzari also served as Vice
President, Clinical Oncology Development for Sanofi-Aventis
(formerly Rhône-Poulenc, Rhône-Poulenc Rorer and Aventis) where he
oversaw the approval of ELOXATIN® (oxaliplatin), TAXOTERE®
(docetaxel) and ELITEK® (rasburicase).
Dr. Bizzari currently serves on the scientific advisory boards
of France’s National Cancer Institute and the European Organisation
for Research and Treatment of Cancer. He also serves on the
scientific advisory boards and board of directors at numerous
global pharmaceutical companies. Dr. Bizzari has received various
industry honors and has authored hundreds of scientific articles
and publications.
Dr. Bizzari received his medical degree from the University of
Nice and has trained at the Pitié-Salpêtrière Hospital in Paris,
the Ontario Institute for Cancer Research, and the McGill Rosalind
and Morris Goodman Cancer Research Centre (formerly the McGill
Cancer Center) in Montreal, Canada.
“With a proprietary ADC platform validated by the FDA approval
of ZYNLONTA®, a robust pipeline of solid tumor targets and a global
team committed to transforming patients’ lives, ADC Therapeutics is
poised to build on its success,” said Dr. Bizzari. “I look forward
to working with the Board to continue ADC Therapeutics’ positive
momentum and make a meaningful difference for patients with
difficult-to-treat cancers.”
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage
biotechnology company improving the lives of those affected by
cancer with its next-generation, targeted antibody drug conjugates
(ADCs). The Company is advancing its proprietary PBD-based ADC
technology to transform the treatment paradigm for patients with
hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab
tesirine-lpyl) is approved by the FDA for the treatment of relapsed
or refractory diffuse large b-cell lymphoma after two or more lines
of systemic therapy. ZYNLONTA is also in development in combination
with other agents. Cami (camidanlumab tesirine) is being evaluated
in a pivotal Phase 2 trial for relapsed or refractory Hodgkin
lymphoma and in a Phase 1b clinical trial for various advanced
solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics
has multiple ADCs in ongoing clinical and preclinical
development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and
has operations in London, the San Francisco Bay Area and New
Jersey. For more information, please visit
https://adctherapeutics.com/ and follow the Company on Twitter and
LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
Forward-Looking Statements
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business and commercialization strategy, market
opportunities, products and product candidates, research pipeline,
ongoing and planned preclinical studies and clinical trials,
regulatory submissions and approvals, projected revenues and
expenses and the timing of revenues and expenses, timing and
likelihood of success, as well as plans and objectives of
management for future operations, are forward-looking statements.
Forward-looking statements are based on our management’s beliefs
and assumptions and on information currently available to our
management. Such statements are subject to risks and uncertainties,
and actual results may differ materially from those expressed or
implied in the forward-looking statements due to various factors,
including those described in our filings with the U.S. Securities
and Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this document speak only as of the date of this press release.
We expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220701005047/en/
Investors Eugenia Litz ADC Therapeutics
Eugenia.Litz@adctherapeutics.com +44 7879 627205 Amanda Hamilton
ADC Therapeutics amanda.hamilton@adctherapeutics.com +1
917-288-7023 Media Mary Ann Ondish ADC Therapeutics
maryann.ondish@adctherapeutics.com +1 914-552-4625
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Apr 2024 to May 2024
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From May 2023 to May 2024